Encephalitis Treatment Market Analysis

Encephalitis Treatment Market Analysis

To get key market trends

  Download Free Sample

Based on disease type, the market is subdivided into primary and secondary encephalitis. The primary encephalitis segment dominated global encephalitis treatment market in 2022. Primary encephalitis refers to brain inflammation caused by a viral or bacterial infection. It is the most common type of encephalitis due to herpes simplex viruses, varicella zoster viruses, and rubella viruses. Viruses are the major cause of primary encephalitis and approximately 70% of the cases are caused due to viruses. Increasing prevalence of encephalitis drives the segment landscape.
 

Based on treatment type, the global encephalitis treatment market is classified into antiviral agents, steroids, antibiotics, immunoglobulin therapy, plasmapheresis, and other treatments. The antiviral agent segment accounted for the largest share in 2022. The antiviral agents are used for treating primary encephalitis, which is caused by various viruses. Factors such as the increasing prevalence of primary encephalitis, growing demand for treatment, cost-effectiveness, easy availability, efficiency, and increased prescription rate are contributing to the growth of this segment.
 

Based on route of administration, the encephalitis treatment market is subdivided into oral, parenteral, and other routes of administration. The oral segment held the highest market share in 2022 owing to high adoption, non-invasiveness, patient compliance, and convenience. Many of the drugs used for encephalitis treatment are administered orally; for instance, Acyclovir, valacyclovir, and famciclovir are available as oral formulations. These factors will enhance the overall market share.
 

Based on end-user, the encephalitis treatment market is subdivided into hospitals, specialty clinics, and other end-users. Among the end-user segments, the hospital segment held the highest revenue share of the market in 2022. The increasing prevalence of encephalitis, development of new therapies for treating encephalitis, growing government initiatives in launching the new drugs, and increased number of admissions for encephalitis in hospitals accelerated the growth of this segment.
 

Based on region, encephalitis treatment market is subdivided into North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. In 2022, the North America held the highest revenue in this market, owing to an increased prevalence of encephalitis, increasing investments for R&D for developing new drugs for treating encephalitis, presence of key players, and well-developed healthcare infrastructure. During the forecast period, Asia Pacific segment is anticipated to witness significant growth due to the raising prevalence of encephalitis and increased government initiatives and fundings.
 

In North America segment, U.S. accounted for the highest market share in 2022 owing to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and growing awareness and demand for encephalitis treatment.